Amgen Stock Drops After Positive Dazodalibep Results
Amgen stock closed at $406.04 on Nasdaq on September 24, 2026, representing a decline of 9.17% from its 52-week high of $447.03. The decrease comes after the company announced positive results for dazodalibep in a Phase 3 study for systemic Sjogren's disease.
The OASIZ 301 trial involved approximately 621 participants, and showed significant improvement in disease activity as early as Week 4, with sustained progress through Week 48. This marks the expansion of Amgen's pipeline beyond its established medications.
However, the company also announced that detailed data for dazodalibep will be presented at a future medical meeting, and the related OASIZ 303 study is expected to conclude in Q4 2026. These upcoming milestones may impact regulatory timing and treatment durability.